---
id: idsa-amr-guidance-2024
title: "IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections"
short_title: "IDSA AMR Gram-Negative 2024"

organization: Infectious Diseases Society of America
collaborators: null
country: US
url: https://www.idsociety.org/practice-guideline/amr-guidance/
doi: 10.1093/cid/ciae403
pmid: null
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: other
conditions:
  - antimicrobial resistance
  - ESBL infections
  - carbapenem-resistant Enterobacterales
  - Pseudomonas aeruginosa
tags:
  - ESBL-E
  - CRE
  - DTR-P aeruginosa
  - multidrug resistance
  - ceftriaxone-resistant
  - carbapenemase

publication_date: 2024-08-07
previous_version_date: 2023-01-01
status: current
supersedes: idsa-amr-guidance-2023
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Guidance for treatment of infections caused by extended-spectrum Î²-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and difficult-to-treat Pseudomonas aeruginosa (DTR-P. aeruginosa).

## Notes

Living document updated regularly as new evidence emerges. Addresses commonly encountered AMR infections in US hospitals. Provides organism-specific treatment recommendations.
